A cohort profile of the Graham Roberts study cohort

Beth Russell; Poppy Leech; Harriet Wylie; Charlotte Louise Moss; Anna Haire; Deborah Enting; Suzanne Amery; Kathryn Chatterton; Muhammad Shamim Khan; Ramesh Thurairaja; Rajesh Nair; Sachin Malde; Kate Smith; Cheryl Gillett; Debra Josephs; Elias Pintus; Sarah Rudman; Simon Hughes; Clare Relton; Mieke Van Hemelrijck

doi:10.3389/fonc.2023.1334183

A cohort profile of the Graham Roberts study cohort

Front Oncol. 2024 Jan 9:13:1334183. doi: 10.3389/fonc.2023.1334183. eCollection 2023.

Authors

Beth Russell¹, Poppy Leech¹, Harriet Wylie¹, Charlotte Louise Moss¹, Anna Haire¹, Deborah Enting², Suzanne Amery², Kathryn Chatterton², Muhammad Shamim Khan², Ramesh Thurairaja², Rajesh Nair², Sachin Malde², Kate Smith², Cheryl Gillett³, Debra Josephs², Elias Pintus², Sarah Rudman², Simon Hughes², Clare Relton⁴, Mieke Van Hemelrijck¹

Affiliations

¹ Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
² Urology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
³ King's Health Partners Cancer Biobank, King's College London, London, United Kingdom.
⁴ Wolfson Institute of Population Health, Queen Mary University of London, London Sheffield, United Kingdom.

Abstract

Purpose: The Graham Roberts Study was initiated in 2018 and is the first Trials Within Cohorts (TwiCs) study for bladder cancer. Its purpose is to provide an infrastructure for answering a breadth of research questions, including clinical, mechanistic, and supportive care centred questions for bladder cancer patients.

Participants: All consented patients are those aged 18 or older, able to provide signed informedconsent and have a diagnosis of new or recurrent bladder cancer. All patients are required to have completed a series of baseline questionnaires. The questionnaires are then sent out every 12 months and include information on demographics and medical history as well as questionnaires to collect information on quality of life, fatigue, depression, overall health, physical activity, and dietary habits. Clinical information such as tumor stage, grade and treatment has also been extracted for each patient.

Findings to date: To date, a total of 125 bladder cancer patients have been consented onto the study with 106 filling in the baseline questionnaire. The cohort is made up of 75% newly diagnosed bladder cancer patients and 66% non-muscle invasive bladder cancer cases. At present, there is 1-year follow-up information for 70 patients, 2-year follow-up for 57 patients, 3-year follow-up for 47 patients and 4-year follow-up for 19 patients.

Future plans: We plan to continue recruiting further patients into the cohort study. Using the data collected within the study, we hope to carry out independent research studies with a focus on quality of life. We are also committed to utilizing the Roberts Study Cohort to set up and commence an intervention. The future studies and trials carried out using the Roberts Cohort have the potential to identify and develop interventions that could improve the prevention, diagnosis, and treatment of bladder cancer.

Keywords: cohort profile; muscle invasive bladder cancer (MIBC); non-muscle invasive bladder cancer (NMIBC); questionnaires; trials within cohorts.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding for the initial set up of the study was kindly provided by the Graham and Dianne Roberts Charitable Settlement.